Possible unit disposals wouldn't move the needle

If this is all that comes out of Allergan's strategic review, it won't be enough to satisfy angry investors and possible activists

Bold” is Allergan PLC's adjective of choice, trotted out frequently by CEO Brent Saunders and others at the Botox maker. Too bad the potential sale of its women’s health and antibiotic units, reported initially by CNBC and confirmed by the company Wednesday, doesn’t quite qualify.  

In a vacuum, it’s a fine enough move. It would streamline the company and could net a bit of extra cash. But like the Coolsculpting fat-freezing technology Allergan bought last year, it would be more of a minor procedure than major surgery. The fact is, Allergan has deeper problems than asset bloat, and if this is